No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine--dolutegravir

AIDS. 2020 May 1;34(6):956-957. doi: 10.1097/QAD.0000000000002495.

Authors

Arturo Ciccullo¹, Alex Dusina¹, Anna Pia Lassandro¹, Alberto Borghetti², Gianmaria Baldin³, Simona Di Giambenedetto^{1

2}

Affiliations

¹ Infectious Diseases Section, Department of Safety and Bioethics, Catholic University of the Sacred Heart.
² Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome.
³ Mater Olbia Hospital, Olbia, Italy.

PMID: 32271256
DOI: 10.1097/QAD.0000000000002495

No abstract available

Publication types

Comment

MeSH terms

Adipose Tissue
Anti-HIV Agents*
HIV Infections*
Heterocyclic Compounds, 3-Ring
Humans
Lamivudine
Oxazines
Piperazines
Pyridones
Weight Gain

Substances

Anti-HIV Agents
Heterocyclic Compounds, 3-Ring
Oxazines
Piperazines
Pyridones
Lamivudine
dolutegravir